相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Pharmacokinetic and pharmacodynamic analysis of fulvestrant in preclinical models of breast cancer to assess the importance of its estrogen receptor-alpha degrader activity in antitumor efficacy
Suzanne E. Wardell et al.
BREAST CANCER RESEARCH AND TREATMENT (2020)
The Dysregulated Pharmacology of Clinically Relevant ESR1 Mutants is Normalized by Ligand-activated WT Receptor
Kaitlyn J. Andreano et al.
MOLECULAR CANCER THERAPEUTICS (2020)
Circulating tumour DNA analysis to direct therapy in advanced breast cancer (plasmaMATCH): a multicentre, multicohort, phase 2a, platform trial
Nicholas C Turner et al.
LANCET ONCOLOGY (2020)
Endocrine therapy-based treatments in hormone receptor-positive/HER2-negative advanced breast cancer: systematic review and network meta-analysis
Mariana Brandao et al.
ESMO OPEN (2020)
Beyond estrogen: advances in tissue selective estrogen complexes and selective estrogen receptor modulators
J. V. Pinkerton et al.
CLIMACTERIC (2019)
Impact of Breast Cancer Subtypes on Prognosis of Women with Operable Invasive Breast Cancer: A Population-based Study Using SEER Database
Ki-Tae Hwang et al.
CLINICAL CANCER RESEARCH (2019)
New insights into acquired endocrine resistance of breast cancer
Ping Fan et al.
CANCER DRUG RESISTANCE (2019)
Allele-Specific Chromatin Recruitment and Therapeutic Vulnerabilities of ESR1 Activating Mutations
Rinath Jeselsohn et al.
CANCER CELL (2018)
Specific stereochemistry of OP-1074 disrupts estrogen receptor alpha helix 12 and confers pure antiestrogenic activity
S. W. Fanning et al.
NATURE COMMUNICATIONS (2018)
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Freddie Bray et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2018)
Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer
N. C. Turner et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
The SERM/SERD bazedoxifene disrupts ESR1 helix 12 to overcome acquired hormone resistance in breast cancer cells
Sean W. Fanning et al.
ELIFE (2018)
Structural underpinnings of oestrogen receptor mutations in endocrine therapy resistance
John A. Katzenellenbogen et al.
NATURE REVIEWS CANCER (2018)
Different epigenetic mechanisms of ERα implicated in the fate of fulvestrant-resistant breast cancer
Kouki Tsuboi et al.
JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY (2017)
20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years
Hongchao Pan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Palbociclib Combined with Fulvestrant in Premenopausal Women with Advanced Breast Cancer and Prior Progression on Endocrine Therapy: PALOMA-3 Results
Sibylle Loibl et al.
ONCOLOGIST (2017)
The Evolving Role of the Estrogen Receptor Mutations in Endocrine Therapy-Resistant Breast Cancer
Rinath Jeselsohn et al.
CURRENT ONCOLOGY REPORTS (2017)
Fulvestrant in advanced breast cancer: evidence to date and place in therapy
Katalin Boer
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2017)
Structurally Novel Antiestrogens Elicit Differential Responses from Constitutively Active Mutant Estrogen Receptors in Breast Cancer Cells and Tumors
Yuechao Zhao et al.
CANCER RESEARCH (2017)
Mutation site and context dependent effects of ESR1 mutation in genome-edited breast cancer cell models
Amir Bahreini et al.
BREAST CANCER RESEARCH (2017)
Breast Cancer Chemoprevention: A Network Meta-Analysis of Randomized Controlled Trials
Simone Mocellin et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2016)
Breast Cancer Chemoprevention: A Network Meta-Analysis of Randomized Controlled Trials
Simone Mocellin et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2016)
A Preclinical Model for ERα-Positive Breast Cancer Points to the Epithelial Microenvironment as Determinant of Luminal Phenotype and Hormone Response
George Sflomos et al.
CANCER CELL (2016)
Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial
John F. R. Robertson et al.
LANCET (2016)
Estrogen receptor alpha somatic mutations Y537S and D538G confer breast cancer endocrine resistance by stabilizing the activating function-2 binding conformation
Sean W Fanning et al.
eLife (2016)
Efficacy of SERD/SERM Hybrid-CDK4/6 Inhibitor Combinations in Models of Endocrine Therapy-Resistant Breast Cancer
Suzanne E. Wardell et al.
CLINICAL CANCER RESEARCH (2015)
Measuring Residual Estrogen Receptor Availability during Fulvestrant Therapy in Patients with Metastatic Breast Cancer
Michel van Kruchten et al.
CANCER DISCOVERY (2015)
Emergence of Constitutively Active Estrogen Receptor-α Mutations in Pretreated Advanced Estrogen Receptor-Positive Breast Cancer
Rinath Jeselsohn et al.
CLINICAL CANCER RESEARCH (2014)
D538G Mutation in Estrogen Receptor-α: A Novel Mechanism for Acquired Endocrine Resistance in Breast Cancer
Keren Merenbakh-Lamin et al.
CANCER RESEARCH (2013)
Bazedoxifene Exhibits Antiestrogenic Activity in Animal Models of Tamoxifen-Resistant Breast Cancer: Implications for Treatment of Advanced Disease
Suzanne E. Wardell et al.
CLINICAL CANCER RESEARCH (2013)
ESR1 ligand-binding domain mutations in hormone-resistant breast cancer
Weiyi Toy et al.
NATURE GENETICS (2013)
An update on selective estrogen receptor modulators for the prevention and treatment of osteoporosis
Barry S. Komm et al.
MATURITAS (2012)
Mechanisms of Endocrine Resistance in Breast Cancer
C. Kent Osborne et al.
ANNUAL REVIEW OF MEDICINE, VOL 62, 2011 (2011)
Breast Cancer Incidence in the Randomized PEARL Trial of Lasofoxifene in Postmenopausal Osteoporotic Women
Andrea Z. LaCroix et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2010)
Cancer stem cells from human breast tumors are involved in spontaneous metastases in orthotopic mouse models
Huiping Liu et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Lasofoxifene, a new selective estrogen receptor modulator for the treatment of osteoporosis and vaginal atrophy
Luigi Gennari
EXPERT OPINION ON PHARMACOTHERAPY (2009)
An intraductal human-in-mouse transplantation model mimics the subtypes of ductal carcinoma in situ
Fariba Behbod et al.
BREAST CANCER RESEARCH (2009)
Selective estrogen-receptor modulators and antihormonal resistance in breast cancer
V. Craig Jordan et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
分享论文
